RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration

Affiliations

¹ Cancer Pain and Palliative Medicine Service, Department of Medical Oncology, Shaare Zedek Medical Center, Jerusalem, Israel.
² Laboratory of Biostatistics, School of Health Sciences, National and Kapodistrian University of Athens and Frontier Science Foundation-Hellas, Athens, Greece.
³ Methodology Direction, EORTC Headquarters, Brussels, Belgium.
⁴ ESMO Head Office, Lugano, Switzerland.
⁵ Medical Oncology Department, Ioannina University Hospital, Ioannina, Greece.
⁶ Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
⁷ Division of Oncology, Medical University Vienna, Vienna, Austria.
⁸ Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
⁹ Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

Comment

Nathan I Cherny et al. J Natl Cancer Inst. 2018.

. 2018 Oct 1;110(10):1142-1143.

doi: 10.1093/jnci/djy029.

¹ Cancer Pain and Palliative Medicine Service, Department of Medical Oncology, Shaare Zedek Medical Center, Jerusalem, Israel.
² Laboratory of Biostatistics, School of Health Sciences, National and Kapodistrian University of Athens and Frontier Science Foundation-Hellas, Athens, Greece.
³ Methodology Direction, EORTC Headquarters, Brussels, Belgium.
⁴ ESMO Head Office, Lugano, Switzerland.
⁵ Medical Oncology Department, Ioannina University Hospital, Ioannina, Greece.
⁶ Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
⁷ Division of Oncology, Medical University Vienna, Vienna, Austria.
⁸ Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
⁹ Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

No abstract available

Comment in

Response.
Tibau A, Molto C, Amir E. Tibau A, et al. J Natl Cancer Inst. 2018 Oct 1;110(10):1145. doi: 10.1093/jnci/djy031. J Natl Cancer Inst. 2018. PMID: 29529214 No abstract available.

Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.
Tibau A, Molto C, Ocana A, Templeton AJ, Del Carpio LP, Del Paggio JC, Barnadas A, Booth CM, Amir E. Tibau A, et al. J Natl Cancer Inst. 2018 May 1;110(5):486-492. doi: 10.1093/jnci/djx232. J Natl Cancer Inst. 2018. PMID: 29244173